Education
About Us
Working with TipRanks
Follow Us
Ekso Bionics Holding (DE:23E2)
:23E2
Earnings Data
Report Date
Jul 24, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.08Last Year’s EPS
-0.12Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 05, 2025
|% Change Since: -12.47%
|Next Earnings Date:Jul 24, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook. While there were significant achievements such as improved gross margin, reduced net loss, and growth in the personal health segment supported by strategic partnerships, these were somewhat offset by a decline in overall revenue and challenges in the enterprise health segment due to economic uncertainties.Company Guidance
During the first quarter of 2025, Ekso Bionics reported a revenue of $3.4 million, down from $3.8 million in the same period of 2024, attributed to capital budget constraints impacting their EksoNR Enterprise Health product. Gross profit stood at $1.8 million, marking a gross margin of 54%, slightly up from 52% in 2024. Operating expenses were stable at $5.3 million compared to $5.2 million in the previous year. The company reduced its net loss to $2.9 million, or $0.12 per share, from $3.4 million, or $0.20 per share, in 2024. Ekso Bionics also improved its cash position, with $8.1 million in cash and restricted cash as of March 31, 2025, up from $6.5 million at the end of 2024. The company's focus is on leveraging new partnerships with distributors like National Seating & Mobility and Bionic P&O to expand the reach of its Ekso Indego Personal exoskeleton, aiming to increase its contribution to revenue while navigating economic uncertainties affecting capital budget allocations in the Enterprise Health segment.Improved Gross Margin
The company reported a gross margin of approximately 54% for Q1 2025, up from 52% in the same period of 2024, driven by cost savings in supply chain and reduction in service costs.
Reduced Net Loss
Net loss for Q1 2025 was $2.9 million, significantly lower than the net loss of $3.4 million in Q1 2024.
Increased Cash and Restricted Cash
The company reported cash and restricted cash of $8.1 million as of March 31, 2025, up from $6.5 million at the end of 2024.
Personal Health Segment Growth
The CMS pricing determination for the Indigo Personal exoskeleton has created significant opportunities. A pipeline of more than 35 Medicare beneficiaries was developed, a 37% increase from the previous quarter.
New Strategic Partnerships
The company engaged PRIA Healthcare for market access services and announced partnerships with Bionic P&O and National Seating & Mobility to expand distribution for Indigo Personal.
---
DE:23E2 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DE:23E2 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2025 | €0.38 | €0.38 | +0.53% |
Mar 03, 2025 | €0.48 | €0.41 | -14.64% |
Oct 28, 2024 | €0.98 | €0.86 | -13.01% |
Jul 29, 2024 | €1.17 | €1.08 | -7.26% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Ekso Bionics Holding (DE:23E2) report earnings?
Ekso Bionics Holding (DE:23E2) is schdueled to report earning on Jul 24, 2025, TBA Not Confirmed.
What is Ekso Bionics Holding (DE:23E2) earnings time?
Ekso Bionics Holding (DE:23E2) earnings time is at Jul 24, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Ekso Bionics Holding stock?
The P/E ratio of EKSO BIONICS is N/A.
What is DE:23E2 EPS forecast?
DE:23E2 EPS forecast for the fiscal quarter 2025 (Q2) is -0.08.
---